Clinical trial
Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
NCT00464698 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00464698 |
|---|---|
| Title | Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) |
| Official title | Duloxetine for the Treatment of Obsessive Compulsive Disorder |
| Acronym | FIJ-MC-1003 |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Obsessive Compulsive Disorder |
| Intervention type | Drug |
| Interventions | Duloxetine |
| Enrollment | 20 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Apr 24, 2007 |
| Last update posted | Mar 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: